Potential of tumore suppressor FBXW7 as one of the therapeutic targets

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K10085
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Digestive surgery
• Research Institution: Gunma University
• Principal Investigator: Yokobori Takehiko 群馬大学, 未来先端研究機構, 講師 (60420098)
• Co-Investigator(Kenkyū-buntansha): 堤 荘一 群馬大学, 医学部附属病院, 講師 (30323356) ; 宮崎 達也 群馬大学, 医学部附属病院, 講師 (70372349) ; 酒井 真 群馬大学, 医学部附属病院, 助教 (70420099) ; 桑野 博行 群馬大学, 大学院医学系研究科, 教授 (90186560) ; 緒方 杏一 群馬大学, 医学部附属病院, 助教 (10448897)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: FBXW7 / 消化器癌

Outline of Final Research Achievements

We previously reported that the expression levels of FBXW7 in gastric cancer tissues were lower than those in non-cancerous tissues. Moreover, the gastric cancer patients with low FBXW7 expression have aggressive phenotypes of gastric cancer and poor prognosis compared to the high expression group. In this study we evaluated the FBXW7 protein expression using IHC. As a result, the low FBXW7 group had tendency of poor prognosis compared to the high expression group. Moreover, the FBXW7 induction by HDAC inhibitor MS-275 was validated in cancer cell lines. The cancer cell lines expressing highly FBXW7 were more sensitive to the anticancer drugs and radiation than control cells The therapeutic strategy to induce the FBXW7 expression by HDAC inhibitors might be a good for refractory gastric cancer patients.

Free Research Field

消化器癌